Can a higher dose of ustekinumab rescue Crohn's patients who lost response?
NCT ID NCT04245215
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study looked at 108 adults with Crohn's disease whose symptoms returned while on standard ustekinumab treatment. Researchers gave them a re-induction infusion and then split them into two groups: one continued the usual shot every 8 weeks, the other got a shot every 4 weeks. The goal was to see if the higher dose could bring back remission and reduce gut inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ustekinumab (a biologic drug given as an infusion or injection)
What this could lead to
If successful, this could show that increasing the dose of ustekinumab helps regain control of Crohn's disease in people who stopped responding to the standard dose.
What could go wrong
This is a small, completed Phase 3 trial with only 108 participants. The results may not apply to all Crohn's patients, and dose escalation can increase side effects like infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ingrid Arijs
Zaventem, 1930, Belgium